A detailed history of Met Life Investment Management, LLC transactions in Kempharm, Inc stock. As of the latest transaction made, Met Life Investment Management, LLC holds 22,866 shares of KMPH stock, worth $112,958. This represents 0.0% of its overall portfolio holdings.

Number of Shares
22,866
Previous 21,149 8.12%
Holding current value
$112,958
Previous $104,000 7.69%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
N/A
1,717 Added 8.12%
22,866 $112,000
Q2 2024

Aug 13, 2024

BUY
N/A
9,357 Added 79.35%
21,149 $104,000
Q1 2024

May 14, 2024

BUY
N/A
11,792 New
11,792 $58,000
Q3 2023

May 09, 2024

BUY
N/A
18,464 New
18,464 $91,000
Q2 2023

Apr 29, 2024

BUY
$4.94 - $6.29 $91,212 - $116,138
18,464 New
18,464 $91,000
Q2 2023

Aug 10, 2023

BUY
$4.94 - $6.29 $91,212 - $116,138
18,464 New
18,464 $91,000
Q4 2021

Feb 15, 2022

SELL
$7.6 - $10.26 $18,354 - $24,777
-2,415 Closed
0 $0
Q3 2021

May 17, 2024

SELL
$8.72 - $13.31 $80,093 - $122,252
-9,185 Reduced 79.18%
2,415 $22,000
Q3 2021

Jun 21, 2023

BUY
$8.72 - $13.31 $21,058 - $32,143
2,415 New
2,415 $22,000
Q3 2021

Mar 22, 2023

SELL
$8.72 - $13.31 $80,093 - $122,252
-9,185 Reduced 79.18%
2,415 $22,000
Q3 2021

Nov 15, 2021

SELL
$8.72 - $13.31 $80,093 - $122,252
-9,185 Reduced 79.18%
2,415 $23,000
Q2 2021

May 17, 2024

SELL
$8.52 - $15.47 $1,635 - $2,970
-192 Reduced 1.63%
11,600 $148,000
Q2 2021

Jun 21, 2023

BUY
$8.52 - $15.47 $98,832 - $179,452
11,600 New
11,600 $148,000
Q2 2021

Mar 22, 2023

BUY
$8.52 - $15.47 $98,832 - $179,452
11,600 New
11,600 $148,000
Q2 2021

Aug 16, 2021

BUY
$8.52 - $15.47 $98,832 - $179,452
11,600 New
11,600 $149,000

Others Institutions Holding KMPH

About KEMPHARM, INC


  • Ticker KMPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 34,493,600
  • Market Cap $170M
  • Description
  • KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds t...
More about KMPH
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.